There is considerable interest in developing new quantitative imaging methods to monitor and predict breast cancer response to neoadjuvant chemotherapy, both prior to and as early as possible during the course of treatment. Diffuse optical spectroscopic imaging (DOSI) allows patients to be followed from baseline through treatment and surgery with a cost-effective, bedside, handheld scanning probe. In this work, we propose to significantly advance the development of harmonized DOSI technology platform and evaluate its performance in five clinical sites on up to 90 neoadjuvant chemotherapy patients. In preliminary patient studies, DOSI quantitative functional endpoints have been shown to be effective in predicting tumor response to chemotherapy within the first week of a two - four month treatment regimen. In the proposed work we will optimize and improve DOSI functionality, standardize clinical measurement and analysis procedures, and evaluate whether DOSI can be used with equivalent overall performance by different operators. Our long-term goal is to identify quantitative clinical endpoints that can be used to inform medical decisions on chemotherapy regimen, duration, and timing of surgery. These non-invasive endpoints are obtained rapidly with no risk/discomfort and could be used as surrogate markers of pathologic response, an established indicator of long-term survival. An archived database of breast cancer spectroscopic markers will be made available to the research community in order to further facilitate new technology development and enhance our understanding of breast cancer chemotherapy. Few technologies have bridged the gap between laboratory prototype and clinically disseminated cancer imaging system. We are now poised to make this transition by creating a standardized and validated DOSI platform, necessary next steps in the translational research process. Ultimately this work is expected to lead to a bedside optical imaging technology that can be used to improve patient outcome by maximizing therapeutic response, minimizing unnecessary toxicity, and optimizing clinical decision-making.
We propose to advance the development of a portable, bedside optical imaging technology capable of monitoring and predicting patient response to breast cancer neoadjuvant chemotherapy. The technology, Diffuse Optical Spectroscopic Imaging (DOSI), will be evaluated in a multi-site study designed to validate optical endpoints of clinical response.
|Hou, Jue; Williams, Joshua; Botvinick, Elliot L et al. (2018) Visualization of Breast Cancer Metabolism Using Multimodal Nonlinear Optical Microscopy of Cellular Lipids and Redox State. Cancer Res 78:2503-2512|
|Cochran, Jeffrey M; Busch, David R; Leproux, Anaïs et al. (2018) Tissue oxygen saturation predicts response to breast cancer neoadjuvant chemotherapy within 10 days of treatment. J Biomed Opt 24:1-11|
|Leproux, Anaïs; O'Sullivan, Thomas D.; Cerussi, Albert et al. (2017) Performance assessment of diffuse optical spectroscopic imaging instruments in a 2-year multicenter breast cancer trial J Biomed Opt 22:121604|
|Yazdi, Hossein S; O'Sullivan, Thomas D; Leproux, Anais et al. (2017) Mapping breast cancer blood flow index, composition, and metabolism in a human subject using combined diffuse optical spectroscopic imaging and diffuse correlation spectroscopy. J Biomed Opt 22:45003|
|Wright, Heather J; Hou, Jue; Xu, Binzhi et al. (2017) CDCP1 drives triple-negative breast cancer metastasis through reduction of lipid-droplet abundance and stimulation of fatty acid oxidation. Proc Natl Acad Sci U S A 114:E6556-E6565|
|Cochran, J M; Chung, S H; Leproux, A et al. (2017) Longitudinal optical monitoring of blood flow in breast tumors during neoadjuvant chemotherapy. Phys Med Biol 62:4637-4653|
|McLaren, Christine E; Chen, Wen-Pin; O'Sullivan, Thomas D et al. (2017) Sample size and power determination when limited preliminary information is available. BMC Med Res Methodol 17:75|
|O'Sullivan, Thomas D; No, Keunsik; Matlock, Alex et al. (2017) Vertical-cavity surface-emitting laser sources for gigahertz-bandwidth, multiwavelength frequency-domain photon migration. J Biomed Opt 22:1-8|
|Tromberg, Bruce J; Zhang, Zheng; Leproux, Anaïs et al. (2016) Predicting Responses to Neoadjuvant Chemotherapy in Breast Cancer: ACRIN 6691 Trial of Diffuse Optical Spectroscopic Imaging. Cancer Res 76:5933-5944|
|Hou, Jue; Wright, Heather J; Chan, Nicole et al. (2016) Correlating two-photon excited fluorescence imaging of breast cancer cellular redox state with seahorse flux analysis of normalized cellular oxygen consumption. J Biomed Opt 21:60503|
Showing the most recent 10 out of 35 publications